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Successful treatment of massive pulmonary embolism with reteplase
Masif pulmoner embolinin reteplaz ile başarılı tedavisi
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Özet– Nedeni açıklanamayan ve beklenmeyen hastane 
dışı kalp durmasında prognoz kötüdür. Ayırıcı tanı aşama-
sında karşılaşılan güçlükler spesifik tedavi uygulanmasını 
kalp durmasına neden olan geri döndürülebilir faktörlere 
müdahale edilmesini geciktirmektedir. Yoğun pulmoner em-
boli kalp durmasının geri döndürülebilir bir nedenidir ancak 
spesifik tedavi uygulanmazsa yüksek mortaliteye sahiptir. 
Burada yoğun pulmoner emboli nedeniyle başvuran elli üç 
yaşındaki kadın hasta sunuldu.
Summary– Unexpected and unexplained out-of-hospital 
cardiac arrests have a poor prognosis. Difficulties encoun-
tered during the differential diagnosis phase may delay the 
administration of specific treatment for treatable and re-
versible causes of cardiac arrest. Massive pulmonary em-
bolism is a reversible cause of cardiac arrest, but without 
proper management it has a high mortality rate. Presently 
described is the case of a 53-year-old female patient with a 
massive pulmonary embolism.
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A traumatic cardiac arrest in an adult previously known as healthy should be promptly evaluated 
with a differential diagnosis during ongoing car-
diopulmonary resuscitation.[1] A massive pulmonary 
embolism may be the etiological factor behind car-
diac arrest in these patients, and it is a treatable and 
potentially reversible process.[2] If there is a high sus-
picion of massive pulmonary embolism, thrombolytic 
treatment is strongly advised for short-term survival 
and the long-term prognosis. Reteplase is easy to use 
to treat a hemodynamically unstable, massive pul-
monary embolism.
Described in this report is a case of massive pul-
monary embolism presenting with cardiac arrest that 
was successfully treated with reteplase, a third gener-
ation thrombolytic agent.
CASE REPORT
A 53-year-old female patient was admitted to the emer-
gency service with a loss of consciousness following 
respiratory distress. Her initial rhythm was pulseless 
electrical activ-
ity (PEA). While 
cardiopulmonary 
resuscitation was 
performed, her rela-
tives relayed the information that she had arthroscopic 
knee surgery 5 days earlier and had been immobile 
since discharge. Bedside transthoracic echocardio-
graphy (TTE) revealed excess dilatation of the right 
heart chambers and a right ventricular wall motion 
abnormality. In light of the patient’s personal history 
of immobility and the echocardiography findings, 
it was thought that a massive pulmonary embolism 
was the most probable diagnosis for circulatory col-
lapse and cardiac arrest. Reteplase, a third-generation 
thrombolytic agent, and a weight-adjusted unfraction-
ated heparin bolus were administered intravenously. 
Reteplase was given as 2 separate bolus injections of 
10 IU 30 minutes apart. After administration of the 
first bolus of reteplase, recovery of spontaneous circu-
lation (ROSC) was achieved in 6 minutes. Blood pres-
sure was supported with intravenous fluid replacement 
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Abbreviations:
PEA Pulseless electrical activity
TTE Transthoracic echocardiography
ROSC Recovery of spontaneous circulation
CASE REPORT
according to central venous pressure and the provision 
of positive inotropes was also required in the first few 
hours of hospitalization. Following hemodynamic sta-
bilization, thoracic computerized tomography with a 
contrast agent injection was performed and a blood 
clot in the right pulmonary artery was documented 
(Fig. 1). Acute thrombosis in the right deep femoral 
vein was also detected with lower extremity duplex 
ultrasonography. The patient was extubated on the 
second day of hospitalization and there were no neu-
rological complications. She was discharged without 
any medical problem after 1 week of hospitalization. 
Anticoagulation with warfarin was initiated, but due 
to unstable international normalized ratio values, ri-
varoxaban 20 mg per day was substituted as the anti-
coagulant 1 month later. Follow-up TTE examinations 
demonstrated that the right ventricular dilatation and 
dysfunction had receded and the mean pulmonary ar-
terial pressure was under 15 mm Hg.
DISCUSSION
Pulmonary embolism is the third leading cause of 
death due to cardiovascular disease, following my-
ocardial infarction and stroke. Only 4.2% of all pul-
monary embolism patients present in a hemodynam-
ically unstable condition or cardiac arrest, but the 
clinical prognosis is worse for these patients and the 
overall mortality is as high as 58.3%.[3] Treatable and 
reversible etiological causes of cardiac arrest should 
be considered during cardiopulmonary resuscita-
tion. Massive pulmonary embolism is a potentially 
reversible process and is responsible for 13% of un-
explained, unexpected cardiac arrests outside of the 
hospital.[4] Pulmonary circulatory restoration with the 
administration of a thrombolytic agent can be life-sav-
ing in these cases; however, difficulties in performing 
a differential diagnosis during ongoing cardiopul-
monary resuscitation can delay the administration 
of a thrombolytic agent. A recently published paper 
evaluated out-of-hospital cardiac arrest patients man-
aged with pre-hospital administration of reteplase.[5] 
Pre-hospital reteplase was not related to a greater rate 
of ROSC; however, only 3  (7%) of 43 patients had a 
proven pulmonary embolism as the cause of cardiac 
arrest. The majority of the study population com-
prised acute coronary syndrome patients. Clinicians 
have to decide on treatment based on a limited per-
sonal history, initial physical examination findings, 
and bedside diagnostic tools. The survival rate and 
long-term clinical outcomes are definitely better with 
the early administration of thrombolytics in massive 
pulmonary embolism patients presenting in cardiac 
arrest or periarrest condition. A retrospective study re-
ported a 30% rate of thrombolytic agent usage among 
hemodynamically unstable pulmonary embolism pa-
tients.[6] On the other hand, there are few guideline 
proposals for the choice of thrombolytic agent type.[7]
There are some clues available for the differen-
tial diagnosis in these patients. For example, PEA is 
often associated with massive pulmonary embolism 
and PEA is the most commonly seen initial rhythm 
in massive pulmonary embolism patients presenting 
with circulatory collapse.[8] After ROSC, a harsh/loud 
systolic murmur and thrill can be heard, especially 
from an Erb’s point focus, on auscultation. A paraster-
nal lift can be felt with palpation. These physical ex-
amination findings are related to an abrupt increase 
in pulmonary arterial resistance and right ventricular 
workload. Courtney et al.[8] offered a triad to predict 
the possibility of massive pulmonary embolism as 
the cause of cardiac arrest. According to this triad, a 
massive pulmonary embolism may be the responsible 
factor for an atraumatic, witnessed cardiac arrest of 
a patient younger than 65 years of age with an initial 
rhythm of PEA. Some prearrest conditions that may 
be related to a massive pulmonary embolism were 
also defined in the same study: respiratory distress, 
a shock index (pulse/systolic blood pressure) greater 
than 0.8 and altered mental status. Despite the lack 
of diagnostic certainty, if the most probable differen-
tial diagnosis of cardiac arrest is massive pulmonary 
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Figure 1. Thoracic computerized tomography with a con-
trast agent injection revealed a blood clot in the right pul-
monary artery.
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embolism, thrombolytic treatment should be adminis-
tered as soon as possible. Successful thrombolysis is 
associated with faster ROSC and better clinical out-
comes in these patients.[9]
The first clinical study investigating the effective-
ness of thrombolytic treatment in massive pulmonary 
embolism patients with unstable hemodynamic sta-
tus included a 1-hour infusion protocol of streptok-
inase. However, this relatively long infusion period 
is not suitable for patients presenting with cardiac 
arrest and ongoing cardiopulmonary resuscitation. 
In a retrospective study, Le Conte et al.[10] evaluated 
the result of alteplase treatment given as 0.6 mg/kg 
in a 15-minute bolus, and a shorter infusion time was 
found to be correlated with a lower mortality rate and 
did not cause an increase in bleeding complications. 
In the current pulmonary embolism guidelines of the 
European Society of Cardiology,[7] this shorter infu-
sion protocol has been advised for hemodynamically 
unstable massive pulmonary embolism patients (0.6 
mg/kg alteplase in a 15-minute infusion).
Reteplase is a third-generation, fibrin-specific 
thrombolytic agent, and is a recombinant form of 
alteplase. Reteplase binds to fibrin rich clots. There 
are case reports about the use of reteplase in massive 
pulmonary embolism patients presenting with cardiac 
arrest or a prearrest condition.[11] Tebbe et al.[12] com-
pared reteplase and alteplase in hemodynamically sta-
ble massive pulmonary embolism patients and did not 
find any significant difference in the decrease of pul-
monary vascular resistance. This study demonstrated 
that reteplase was at least as effective as alteplase in 
massive pulmonary embolism. However, we do not 
have any proposal in the current guidelines for the 
usage of reteplase in massive pulmonary embolism.
[7] Reteplase can be a good candidate for massive pul-
monary embolism patients presenting in a hemody-
namically unstable condition, cardiac arrest, or with 
prearrest status since it is easy to administer as a bolus 
and there is no need for a dosing adjustment. Effec-
tive cardiopulmonary resuscitation with proper chest 
compressions and good ventilation is very important 
in these patients in order to provide sufficient time for 
reteplase activity to be visible. We have to emphasize 
the risk of major bleeding with thrombolytic therapy. 
The risk for major bleeding especially increases with 
advancing age. The individualized bleeding risk of a 
patient must be assessed before administering throm-
bolytic treatment. A previous study[13] compared 
reteplase and alteplase in terms of efficacy and safety 
in the treatment of acute myocardial infarction and 
found similar hemorrhagic stroke rates between the 
two. There was a slightly higher (2.5% vs. 1.7%) but 
statistically non-significant incidence of hemorrhagic 
stroke in patients over 75 years of age in the reteplase 
group. Tenecteplase is another third-generation throm-
bolytic agent. In the ASSENT-2 trial (Assessment of 
the Safety and Efficacy of a New Thrombolytic), its 
efficacy was similar to that of alteplase, with fewer 
bleeding complications.[14]
In addition to life-saving benefits, absolute and 
relative contraindications have been defined for the 
administration of thrombolytic treatment.[15] Abso-
lute contraindications are prior intracranial hem-
orrhage, known structural cerebral vascular lesion, 
known malignant intracranial neoplasm, ischemic 
stroke within 3 months, active internal bleeding, and 
suspected aortic dissection. In situations where abso-
lute contraindications apply, alternative, mechanical 
reperfusion strategies such as echosonic thrombol-
ysis or rheolytic thrombectomy can be useful. Our 
patient had some relative contraindications: recent 
minor arthroscopic surgery and prolonged cardiopul-
monary resuscitation. In cases with relative con-
traindications, the risk-benefit assessment depends 
on the physician’s preference and the bedside evalu-
ation. Although our patient had relative contraindica-
tions, he was considered to remarkably benefit from 
thrombolytic therapy, owing to circulatory collaps 
and a highly suspected pulmonary embolism as sup-
ported by bedside echocardiography.
Early thrombolytic treatment, even during ongo-
ing cardiopulmonary resuscitation, can be life-sav-
ing and improve short- and long-term clinical out-
comes. The patient’s personal history, initial physical 
findings, and initial monitor rhythm and bedside 
TTE results are the only choices to make a proper 
differential diagnosis with a high clinical suspicion 
of massive pulmonary embolism presenting with 
cardiac arrest. Easy-to-use third-generation throm-
bolytic agents such as reteplase or tenecteplase can 
be good candidates for treatment.
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